Menu

Accurate Monitoring by Specialist Teams Reduces the Time Between Breast Cancer Screening and Initial Surgical Treatment.

Background

Over 266,000 women are newly diagnosed with breast cancer every year in the United States, roughly 21% of all breast cancer patients die of the disease annually. 1 Many studies have been conducted to evaluate how delays in diagnosis and treatment can result in adverse patient outcomes. Factors including tumor size and stage, socioeconomic status, race/ethnicity, as well as hospital size and capabilities have been shown to influence outcomes.

Obtenga las actualizaciones de Knowledge Pathway directamente en su bandeja de entrada.

Si ha realizado un seminario web educativo de nuestra serie mensual y desea solicitar créditos de formación continua a su organización certificadora, descargue el formulario para que podamos ayudarle a añadir créditos educativos autodeclarados a su expediente académico.

SOLICITAR CRÉDITOS EDUCATIVOS AUTODECLARADOS

Variations in care delivery and turnaround times can be reduced by accurately examining the patient care path from initial screening mammography to first surgical intervention. We have developed a process to optimize timeliness to initial surgical treatment.

Methods

The process starts with observing care delivery from diagnostic mammogram, biopsy, pathology tissue processing, diagnosis and lumpectomy or mastectomy. A team of process and clinical experts (Leica Biosystems) conducted observations to map out current care delivery processes. Standard national metrics for timeliness within the breast care pathway from the National Consortium of Breast Centers’ was applied to the process map to understand national averages as well as best practices. Timeliness data on 5,571 patients from over 250 breast centers across the country from the NQMBC (National Quality Measures for Breast Centers) database was utilized to review time intervals and intradepartmental hand offs that impact progression through the breast care pathway.

Six sigma, black belt specialists conducted an analysis of current breast center processes, identified specific sites for improvement, integrated their recommendations and completed the cycle by repeat monitoring of the entire process.

Results

Our specialists have reviewed average and ideal overall performance in timeliness to initial surgical treatment. Improvements may be expected from 22%-75% in timeliness to initial surgical treatment.

Mean * Best Practice **
Time from screening to dx mammo 6.0 4.9
Time from dx mammo to bx 5.9 4.1
Time from bx to path report 2.1 1.2
Time from bx to first surgery 22.6 16.9
Total time from screening mammogram to first surgery 36.6 days 27.1 days

*“Mean” is the mean number of business days based on NQMBC July-Dec. 2017 data
** Best Practice is the 75th Percentile based on data in the NQMBC database for July-Dec. 2017

Conclusion

A process to impact the timeliness of care between screening mammography and initial surgical treatment has been developed. Standardized and monitored care delivery processes can result in better efficiency in breast cancer patient care delivery from between 22% - 75%. Using a detailed patient care pathway and black belt specialists to analyze processes, we expect to reduce turnaround times and optimize efficiency across the breast cancer patient’s care pathway.

1 Cancer Facts and Figures 2018; American Cancer Society.

El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.

Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento. Por la presente, Leica Biosystems y los editores renuncian a cualquier responsabilidad que surja directa o indirectamente del uso del contenido, incluido cualquier fármaco, dispositivo, técnica o procedimiento descrito en el contenido.

Copyright © 2021 Leica Biosystems division of Leica Microsystems, Inc. y sus filiales de Leica Biosystems. Todos los derechos reservados. LEICA y el logotipo de Leica son marcas comerciales registradas de Leica Microsystems IR GmbH.

¿Quiere que publiquemos su escrito?

Estamos buscando otros grandes escritores para publicar sus textos aquí. ¡Envíenos una solicitud y nos pondremos en contacto con usted!

¡ENVÍE SU ESCRITO!

¿Le gusta lo que ve?

Obtenga más contenido de Knowledge Pathway como este directamente en su bandeja de entrada. Cancele su suscripción en cualquier momento.